<DOC>
	<DOCNO>NCT02260011</DOCNO>
	<brief_summary>The objective study compare bronchodilator efficacy safety ipratropium bromide HFA-134a inhalation aerosol market , Atrovent® CFC Inhalation Aerosol COPD patient</brief_summary>
	<brief_title>Study Comparability Ipratropium Bromide Hydrofluoroalkane ( HFA ) -134a Inhalation Aerosol Market Standard , Atrovent® Chlorofluorocarbon ( CFC ) Inhalation Aerosol , Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>All patient must diagnosis COPD must meet follow spirometric criterion : Patients must stable , moderate severe airway obstruction FEV 1 ( forced expiratory volume first second ) &lt; =65 % predict normal FEV1 &lt; =70 % FVC ( Forced Vital Capacity ) Males : Predicted normal FEV1=0.093 ( height inch ) 0.032 ( Age ) 1.343 Females : Predicted normal FEV1=0.085 ( height inch ) 0.025 ( Age ) 1.692 Male female patient 40 year age old Patients must smoke history ten packyears Patients must able demonstrate improvement FEV1 &gt; =015 % within one hour inhalation two puff Atrovent® inhalation aerosol ( 21 mcg per puff ) Patients must able satisfactorily administer medication , perform pulmonary function test maintain record study period require protocol All patient must sign informed consent form prior participation trial ( i.e. , prior prestudy washout usual pulmonary medication prior fast laboratory test ) Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Patients clinical relevant baseline hematology , blood chemistry urinalysis . If abnormality defines disease list exclusion criterion , patient exclude All patient serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 80 IU/L ; serum glutamic pyruvic transaminase ( SGPT ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dL , creatinine &gt; 2.0 mg/dL exclude regardless clinical condition . Repeat laboratory evaluation conduct patient Patients history asthma , allergic rhinitis atopy blood eosinophil count 600/mm³ . A repeat eosinophil count conduct patient Patients recent history ( i.e. , one year less ) myocardial infarction Patients recent history ( i.e. , three year less ) heart failure , patient cardiac arrhythmia require therapy , patient receive systemic beta blocker patient chronic daytime oxygen therapy Patients know active tuberculosis Patients history cancer within last five year . Patients treat basal cell carcinoma allow Patients history life threaten pulmonary obstruction , history cystic fibrosis bronchiectasis Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No . 1 Patients upper respiratory tract infection COPD exacerbation six week prior screen visit ( vist1 ) baseline period Patients known hypersensitivity anticholinergic drug Patients know symptomatic prostatic hypertrophy bladder neck obstruction Patients know narrowangle glaucoma Patients cromolyn sodium nedocromil sodium Patients antihistamines Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( e.g. , oral contraceptive , intrauterine device , diaphragm Norplant® ) Patients take investigational drug within one month 6 halflives ( whichever longer ) drug prior screen visit patient currently enrol research study Patients history and/or active alcohol drug abuse Exclusion criterion patient allergy Patients active infectious rhinitis ( common cold ) determine history physical Patients upper low respiratory infection screen</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>